Product Description
an investigational acetyl-CoA carboxylase inhibitor (ACCi) (Sourced from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline)
Mechanisms of Action: ACC Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Hepatitis|Hepatitis, Alcoholic|Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic
Phase 1: Non-alcoholic Steatohepatitis|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Healthy Volunteers|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04395950 |
AAAS9106 | P1 |
Withdrawn |
Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2021-08-19 |
50% |
2021-08-26 |
Primary Endpoints |
NCT03871439 |
C1171007 | P1 |
Completed |
Healthy Volunteers |
2019-05-08 |
50% |
||
NCT03597217 |
C1171013 | P1 |
Completed |
Non-alcoholic Steatohepatitis |
2018-11-15 |
53% |
2019-03-22 |
Treatments |
NCT03534648 |
C3711002 | P1 |
Completed |
Healthy Volunteers |
2018-07-16 |
18% |
2019-03-22 |
Treatments |
NCT03309202 |
C1171006 | P1 |
Completed |
Other |
2018-06-26 |
18% |
2019-03-22 |
|
NCT03448172 |
C1171010 | P1 |
Completed |
Healthy Volunteers |
2018-05-26 |
58% |
2019-03-22 |
Treatments |
NCT02871037 |
C1171001 | P1 |
Completed |
Healthy Volunteers |
2017-03-01 |
2019-03-20 |
||
NCT04399538 |
C3711005 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic |
2022-03-31 |
68% |
2023-04-14 |
|
NCT03776175 |
C3711001 | P2 |
Completed |
Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic |
2019-09-09 |
19% |
2020-03-12 |
Primary Endpoints|Study Completion Date |
2017-001156-55 |
2017-001156-55 | P2 |
Completed |
Fatty Liver, Alcoholic |
2019-03-26 |
35% |
2025-07-05 |
Treatments |
NCT03248882 |
C1171002 | P2 |
Completed |
Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2019-02-26 |
35% |
2019-08-10 |
Primary Completion Date|Primary Endpoints|Treatments |
CTR20210412 |
CTR20210412 | P2 |
Completed |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |